Here's How Much $100 Invested In Medpace Hldgs 5 Years Ago Would Be Worth Today
FDA Issues Warning on Compounded Versions of Novo Nordisk's Semaglutide
Here's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today
AbbVie Exits Alzheimer's Program on Lack of Differentiation
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
Biogen-partnered Alzheimer's Therapy Fails to Clear EU Hurdle
Vertex Pharmaceuticals Analyst Ratings
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Novo Nordisk Shares Decline Amid Competitive Pressure
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Apple To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
Navigating 5 Analyst Ratings For Thermo Fisher Scientific
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Thermo Fisher Scientific Analyst Ratings